Dr. Chavez Discusses Ibrutinib Plus Venetoclax in CLL

Julio Chavez, MD
Published: Monday, Aug 14, 2017


Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses ibrutinib (Imbruvica) plus venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

Sequential treatment is the future of CLL, says Chavez, including the combination of ibrutinib plus venetoxclax and combinations with monoclonal antibodies.

Ibrutinib plus venetoclax is an interesting combination, Chavez says, and further results will be presented at the 2017 ASH Annual Meeting to confirm its potential in this disease.
 
SELECTED
LANGUAGE

Julio Chavez, MD, of the Department of Malignant Hematology at Moffitt Cancer Center, discusses ibrutinib (Imbruvica) plus venetoclax (Venclexta) in chronic lymphocytic leukemia (CLL).

Sequential treatment is the future of CLL, says Chavez, including the combination of ibrutinib plus venetoxclax and combinations with monoclonal antibodies.

Ibrutinib plus venetoclax is an interesting combination, Chavez says, and further results will be presented at the 2017 ASH Annual Meeting to confirm its potential in this disease.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x